| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JAAD.2003.09.014 |
| P698 | PubMed publication ID | 15153885 |
| P50 | author | Steven R. Feldman | Q42775161 |
| James G. Krueger | Q110142760 | ||
| P2093 | author name string | Alan Menter | |
| Gerald G Krueger | |||
| Christopher S Carlin | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 859-866 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis | |
| P478 | volume | 50 |
| Q28550785 | A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis |
| Q48081441 | A pilot study examining mindfulness-based cognitive therapy in psoriasis. |
| Q40066888 | A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis |
| Q53009945 | A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. |
| Q34562148 | Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis |
| Q36108233 | Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images. |
| Q38676598 | Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. |
| Q64891361 | Auricular acupressure as a complementary therapy for psoriasis vulgaris: study protocol for a multicenter randomized controlled trial. |
| Q55002500 | Automated, computer-guided PASI measurements by digital image analysis versus conventional physicians' PASI calculations: study protocol for a comparative, single-centre, observational study. |
| Q24235424 | Biologics for chronic plaque psoriasis |
| Q24242281 | Biologics for chronic plaque psoriasis |
| Q39837952 | Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial |
| Q38042475 | Comparative efficacy of biologics in psoriasis: a review. |
| Q64277547 | Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study |
| Q46945261 | Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States |
| Q36124195 | Current severe psoriasis and the rule of tens. |
| Q34634463 | Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice |
| Q41889404 | Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis. |
| Q56041890 | Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: A community‐oriented study introducing the ‘Beer Sheva Psoriasis Severity Score’ |
| Q89865617 | Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis |
| Q28280465 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) |
| Q28280453 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) |
| Q36094590 | Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis |
| Q33258048 | Evaluation of efalizumab using safe psoriasis control |
| Q48381880 | Evaluation of the impact of writing exercises interventions on quality of life in patients with psoriasis undergoing systemic treatments |
| Q53143623 | Facial Psoriasis Log-based Area and Severity Index: A valid and reliable severity measurement method detecting improvement of facial psoriasis in clinical practice settings. |
| Q37665294 | How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review |
| Q34573366 | Ichthyotherapy as alternative treatment for patients with psoriasis: a pilot study |
| Q36743142 | Immunobiologics in the treatment of psoriasis |
| Q38846063 | Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris |
| Q53167292 | Inter-observer reliability of the PASI in a clinical setting. |
| Q53077820 | Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index). |
| Q94397565 | Interleukin inhibitors for psoriatic arthritis |
| Q31034753 | Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. |
| Q48478885 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years |
| Q53070648 | Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study. |
| Q58434978 | Long-term treatment of plaque psoriasis with efalizumab: an Italian experience |
| Q53035588 | Method of assessing involved facial areas: rule of fours. |
| Q53294714 | Neutrophil-to-lymphocyte ratio decreases after treatment of psoriasis with therapeutic antibodies. |
| Q41366996 | Non-inferiority margins employed in clinical trials in Japan |
| Q37664478 | Novel immunobiologics for psoriasis |
| Q38211315 | Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials |
| Q41460287 | Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris |
| Q34038554 | Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial |
| Q53312205 | Pathogenesis of psoriasis and current challenges. |
| Q38195568 | Patient involvement in outcome measures for psoriatic arthritis |
| Q34196035 | Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting |
| Q44773623 | Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept |
| Q38164204 | Phytotherapy in the management of psoriasis: a review of the efficacy and safety of oral interventions and the pharmacological actions of the main plants. |
| Q58765353 | Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients |
| Q55141743 | Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. |
| Q53508119 | Postacne scarring--a quantitative global scarring grading system. |
| Q35579443 | Psoriasis assessment tools in clinical trials |
| Q40419030 | Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring |
| Q38558139 | Quality of life: a research gap in teledermatology |
| Q35029128 | Relationship between retinal sensitivity and disease activity in patients with psoriasis vulgaris |
| Q33879351 | Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis |
| Q44214421 | Responsiveness to change and interpretability of the simplified psoriasis index |
| Q91685372 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial |
| Q92280996 | Serum homocysteine level, vitamin B12 levels, and erythrocyte folate in psoriasis: A case-control study |
| Q35155926 | Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity |
| Q38283299 | Systematic review of cost-effectiveness analyses of treatments for psoriasis |
| Q48266852 | The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument |
| Q46356347 | The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients |
| Q38644270 | Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials. |
| Q38349779 | Tofacitinib for the treatment of moderate-to-severe psoriasis |
| Q37098135 | Treatment of severe psoriasis with infliximab |
| Q36576962 | Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patients |
| Q38083175 | Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. |
| Q53878167 | [Clinical and histopathological improvement of psoriasis in patients with osteoarthritis treated with chondroitin sulfate: report of 3 cases]. |
| Q80875081 | [Efficacy of short- and long-term efalizumab] |
| Q82663598 | [Outcome parameters for use in psoriatic arthritis] |
| Q26862017 | Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En |
Search more.